Locations:
Abu Dhabi|Canada|Florida|London|Nevada|Ohio|
Gray gradientGray gradient
Cleveland Clinic icon
Consult QD logo
Search IconSearch

Heart, Vascular and Thoracic

23-HVI-4298711_TAVR-vs-SAVR_650x450

TAVR and SAVR Perform Similarly at 5 Years in Low-Risk Patients, PARTNER 3 Report Shows

Five-year data demonstrate convergence of outcomes from years 1 to 5

HVI_Kelley_4277155_Patient Procedure Shoot- First in Human Trial
October 27, 2023/Genomic Medicine

Cleveland Clinic Treats First Patient With Investigational Gene Therapy for Hypertrophic Cardiomyopathy

One-time infusion of adenovirus-based therapy is designed to restore heart muscle function

3D rendering of upper esophageal reflux in a male

Novel Tool Holistically Assesses Patient-Reported Outcomes of Esophageal Conditions

Going beyond the Eckardt symptom score to evaluate dyspepsia, eating and symptom “bother”

23-HVI-4298710_LAAO+TAVR_650x450

Concurrent TAVR and Watchman Placement Is Noninferior to TAVR Plus Medical Therapy for Atrial Fibrillation

Randomized WATCH-TAVR trial confirms safety of the combined procedures

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

maps for ventricular tachycardia ablation

Monomorphic VT Electrical Storm: Is Ischemic or Coronary Evaluation Needed?

Study finds that in the absence of ACS, the yield is low and outcomes are unaffected

illustration of coronary artery with calcified plaque

Coronary Artery Calcium Scoring Improves Accuracy of Cardiovascular Risk Screening

Observational study supports adding CAC score to traditional risk factors for precision medicine approach

image of human brain with an intracranial aneurysm

Intracranial Aneurysm Risk in Marfan Syndrome: Study Reveals Higher-Than-Expected Prevalence

Cleveland Clinic findings prompt efforts for broad data pooling

Blood pressure check

Lorundrostat Safely Lowers Blood Pressure in Uncontrolled Hypertension in Phase 2 Trial

Results inform dose selection for further trials of the aldosterone synthase inhibitor

21-HVI-4131174-CQD-Paclitaxel-coated-devices-for-PAD

Paclitaxel-Coated Devices: How the Process of Ruling Out Safety Concerns Is Improving Vascular Surgery Research

Benefits of new FDA safety determination go beyond expanding patients’ options

23-HVI-4172009 CQD 650×450-2

Updates From CLEAR Outcomes and VALOR-HCM: Expanded Benefits With Bempedoic Acid and Mavacamten

Additional analyses of the two trials presented at 2023 ESC Congress

BackPage 17 of 61Next

Advertisement

Ad